Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- ALCLS.PA
- Price
- 3.40
- Stock movement up
- +0.20 (6.07%)
- Company name
- Cellectis
- Exchange
- (PA ,
- Currency
- EUR )
- Sector
- Healthcare >Biotechnology
- Market cap
- 246.27M
- Ent value
- 443.31M
- Price/Sales
- 4.37
- Price/Book
- 2.54
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -29.83%
- 1 year return
- 91.29%
- 3 year return
- -
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-11-14
DIVIDENDS
ALCLS.PA does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 4.37 |
| Price to Book | 2.54 |
| EV to Sales | 7.87 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 72.33M |
| EPS (TTM) | - |
| FCF per share (TTM) | - |
Income statement
Loading...
Income statement data
| Revenue (TTM) | - |
| Gross profit (TTM) | - |
| Operating income (TTM) | - |
| Net income (TTM) | - |
| EPS (TTM) | - |
| EPS (1y forward) | -1.43 |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 59.81M |
| Net receivables | 29.37M |
| Total current assets | 230.64M |
| Goodwill | 0.00 |
| Intangible assets | 1.15M |
| Property, plant and equipment | 176.23M |
| Total assets | 353.97M |
| Accounts payable | 17.52M |
| Short/Current long term debt | 94.77M |
| Total current liabilities | 167.43M |
| Total liabilities | 256.86M |
| Shareholder's equity | 97.11M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | - |
| Capital expenditures (TTM) | - |
| Free cash flow (TTM) | - |
| Dividends paid (TTM) | - |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | - |
| Return on Invested Capital | - |
| Cash Return on Invested Capital | - |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 3.17 |
| Daily high | 3.40 |
| Daily low | 3.11 |
| Daily Volume | 255K |
| All-time high | 40.90 |
| 1y analyst estimate | 6.50 |
| Beta | 3.04 |
| EPS (TTM) | - |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| ALCLS.PA | S&P500 | |
| Current price drop from All-time high | -91.67% | -2.25% |
| Highest price drop | -97.31% | -19.00% |
| Date of highest drop | 4 Apr 2025 | 8 Apr 2025 |
| Avg drop from high | -95.40% | -2.71% |
| Avg time to new high | - | 5 days |
| Max time to new high | 282 days | 89 days |
COMPANY DETAILS
Marketcap
246.27M
Marketcap category
Small-cap
Description
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing ALLO-501 to treat large B-cell lymphoma; ALLO-316, a gene-edited allogeneic CAR T-cell product targeting CD70; ALLO-819 to treat acute myeloid leukemia; ALLO-213 for the treatment of small cell lung cancer; and ALLO-182 to treat gastric and pancreatic cancer. It also develops UCART22 for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia; UCART123 to treat acute myeloid leukemia; UCART 20x22 for relapsed or refractory B-Cell non-hodgkin's lymphoma; and cema-cel to treat relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. The company was founded in 1999 and is headquartered in Paris, France.
Employees
216
Website
Investor relations
-
SEC filings
CEO
Country
France
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
European equities traded in the US as American depositary receipts were tracking lower late Friday m
November 14, 2025
European equities traded in the US as American depositary receipts were tracking higher late Tuesday
November 11, 2025
The European market has recently experienced a downturn, with the pan-European STOXX Europe 600 Index ending 1.24% lower amid concerns over valuations in artificial intelligence-related stocks. In suc...
November 11, 2025
European equities traded in the US as American depositary receipts opened the week higher late Monda
November 10, 2025
Presented data underscore the potential of lasme-cel (UCART22) and eti-cel (UCART20x22) to improve outcomes in r/r B-ALL and r/r NHL: Lasme-cel in r/r B-ALL (BALLI-01) ORR of 68% with lasme-cel Proces...
November 7, 2025
(Article 223-16 of General Regulation of the French financial markets authority)PARIS, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of sha...
November 7, 2025
European equities traded in the US as American depositary receipts were tracking lower late Friday m
November 7, 2025
European equities traded in the US as American depositary receipts were tracking higher late Wednesd
November 5, 2025
European equities traded in the US as American depositary receipts were little changed late Monday m
November 3, 2025
Preliminary data recently shared for eti-cel (UCART20x22) show an 86% ORR and a 57% CR rate (n=7), underscoring its potential to improve outcomes in r/r NHLPreclinical data demonstrated that combining...
November 3, 2025
Next page